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Abstract
Vectors of trypanosomiasis – tsetse (Glossinidae) in Africa, kissing-bugs (Triatominae) in Latin
America – are very different insects but share demographic characteristics that render them highly
vulnerable to available control methods. For both, the main operational problems relate to re-
invasion of treated areas, and the solution seems to be in very large-scale interventions covering
biologically-relevant areas rather than adhering to administrative boundaries. In this review we
present the underlying rationale, operational background and progress of the various
trypanosomiasis vector control initiatives active in both continents.
Background
The trypanosomiases are amongst the most serious of the
so-called 'neglected tropical diseases' [1]. In the 1980s,
American trypanosomiasis (Chagas disease, due to
Trypanosoma cruzi) was believed to infect over 24 million
people [2] with another 100 million considered at risk,
although these estimates have since been reduced (Fig. 1).
Chagas disease can be fatal in its early acute stage, but
more usually progresses to a debilitating chronic phase –
affecting up to 30% of those infected – involving severe
cardiac lesions and, with some strains, intestinal lesions
resulting in the so-called 'mega-syndrome' of severe intes-
tinal dilations. Because of these debilitating effects, the
World Bank [3] ranked Chagas disease as by far the most
serious of the parasitic diseases affecting Latin America,
with a social and economic impact far in excess of even
the combined impact of other diseases such as malaria,
leishmaniasis and schistosomiasis. By contrast, African
trypanosomiasis (Sleeping Sickness) is invariably fatal if
untreated, with the gambiense form generally causing a
chronic disease leading to fatal sequelae after some years,
and the more acute rhodesiense form often leading to
death in just a few months. But the suite of closely-related
animal trypanosomiases transmitted by tsetse in Africa
(including T. b. brucei, T. vivax, T. congolense, and T. simiae)
have an even greater impact, denying livestock over vast
areas, and affecting agricultural production both directly
and indirectly by limiting the use of draught animals for
transport and ploughing. The World Health Organization
currently estimates some 300,000 cases of human Sleep-
ing Sickness [4], while the economic cost of animal
trypanosomiasis in Africa has been estimated at US$4.75
billion per year [5].
American and African trypanosomiases are difficult to
treat, and vaccines are unavailable. Two drugs – benznida-
zole and nifurtimox – can be used to treat Chagas disease,
but they are currently only used in the acute stage or early
chronic stage of infection, and both can cause severe side
effects, sometimes life-threatening. Nifurtimox can also
be used to treat gambiense Sleeping Sickness, although a
range of other drugs is more widely used (Table 1). None
is ideal, and the most widely used – melarsoprol (some-
times described as "a mixture of arsenic and antifreeze") –
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tends to be lethal for up to 10% of those treated. Other
drugs are used to treat livestock, but tend to be expensive
for African farmers, and show increasing problems of
drug-resistance and drug-counterfeiting [6]. In both conti-
nents therefore, vector control is of crucial importance in
trypanosomiasis control.
The vectors of these trypanosomiases – Triatominae (kiss-
ing bugs) in Latin America, Glossinidae (tsetse-flies) in
Africa – are very different insects, but share certain charac-
teristics that render them highly vulnerable to available
vector control methods. Both are slowly-reproducing –
often described as K-strategists in the terminology of
MacArthur & Wilson [7] – and so have a limited capacity
to repopulate areas where their abundance has been
reduced. Moreover, their demographic strategies tend to
lead to reduced genetic variability within each vector pop-
ulation, limiting their capacity to respond to vector con-
trol interventions through selection of new attributes such
as insecticide-resistance [8]. No tsetse population has yet
been selected for insecticide resistance, and amongst Tri-
atominae only one focus of limited resistance was
detected in Rhodnius prolixus in Venezuela during the
1970s, with some pyrethroid resistance now also being
found amongst some Triatoma infestans populations in
southern Bolivia and northwestern Argentina [9,10].
Control of American trypanosomiasis (Chagas disease)
Chagas disease was first described by Brasilian clinician
Carlos Chagas in 1909. Remarkably, Chagas not only
described the causative agent, Trypanosoma cruzi, with
most of its life-cycle and clinical features, he also
described its vectors and some small animal reservoirs,
and was amongst the pioneers – with José Pellegrino and
Emmanuel Dias – in attempts to control it. The parasite,
and vector species of Triatominae, are widely distributed
in the Americas from the Great Lakes of northern USA to
southern Argentina, generally in a silvatic cycle of trans-
mission involving small nest-building animals such as
opossums, armadillos, and various species of rodent. In
much of Latin America however, species of Triatominae
have adapted to live in the cracks and crevices of rural
dwellings, emerging at night to feed on the sleeping occu-
pants. While feeding, they may defaecate the remains of
their previous bloodmeal, so that if infected, the parasites
in the bug faeces can pass to the human host – especially
across the mucosa of eye, mouth, or nose. As Carlos Cha-
gas observed, since the bugs live in the cracks of poor-
quality rural homes, then improving the houses should
make them less suitable for the bugs, and house improve-
ment programmes remain an important component of
Chagas disease control in many areas. By the 1940s,
attempts were also being made to eliminate domestic Tri-
The rise and fall of Chagas diseaseFigu e 1
The rise and fall of Chagas disease. Estimates of Chagas 
disease prevalence 1960–2007.
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Table 1: Currently available treatments for human trypanosomiasis
Date of
 introduction
Days of treatment Likelihood of 
serious side
 effects
T. cruzi gambiense rhodesiense
early late early late early late
Suramine 1916 - - - - 40a - ++
Pentamidine 1940 - - 7 - - - +/-
Melarsoprol 1949 - - - 10–30b - 10–30b +++++
Nifurtimox 1967 30–60 - - 15–30c - - ++
Benznidazole 1972 30–60 - - - - - ++
Eflornithine 1990 - - - 7–14d - - ++
a Suramine: 1 injection per week for 5 weeks
b Melarsoprol: new regime being developed of 1 daily injection for 10 days
c Nifurtimox: not yet registered for use against gambiense, but is being used on compassionate grounds when other treatments fail
d Eflornithine: 4 intravenous perfusions per day
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atominae by spraying kerosene over house walls, and even
using military flame-throwers. But synthetic insecticides
proved more effective (and less hazardous). Organochlo-
rines such as BHC (lindane) and dieldrin were widely
used until being progressively replaced by synthetic pyre-
throids during the 1980s.
Venezuela in the 1960s [11] and also the Brasilian state of
São Paulo [12], had shown that it was feasible to elimi-
nate domestic Triatominae from rural houses by a consist-
ent and widespread campaign of indoor insecticide
spraying. This experience, coupled with pilot control trials
in many other areas, laid the basis for the Brasilian
national Chagas disease control programme, launched in
1983 with the declared objective of eradicating the main
domestic vector, Triatoma infestans, which appeared to
have no silvatic foci in Brasil. This campaign was highly
successful. By 1986, T. infestans had been eliminated from
almost 80% of its previously-known distribution in Brasil
[13] but the programme was then halted due to outbreaks
of dengue in the main coastal cities of Brasil – the 600 or
so field staff of the rural Chagas control programme were
abruptly withdrawn and sent to hunt Aedes aegypti in the
urban areas, and the Chagas control programme col-
lapsed.
This Brasilian campaign showed two important lessons.
Firstly, the methods and operational strategy appeared
adequate, such that there seemed no technical impedi-
ment to eliminating domestic Triatominae on a large-
scale. But secondly, achieving this objective would be
impossible if similar interventions were not also being
carried out in neighbouring countries (T. infestans is no
respecter of national boundaries), and would require a
continued political commitment to maintain the cam-
paign until its objectives had been reached. The enlight-
ened response was the Southern Cone Initiative, a
multinational programme designed to eliminate domes-
tic T. infestans throughout its known distribution not just
in Brasil, but also in Argentina, Bolivia, Chile, Paraguay,
Uruguay, and southern Peru [14]. Approved by Ministers
of Health in 1991 (Resolution 04-3-CS) and coordinated
by the Pan American Health Organization (PAHO), the
work of the Southern Cone Initiative began in 1992, with
vector control interventions progressively covering the
whole distribution of T. infestans – an area estimated at
just over 6 million Km2. At the time of writing, the distri-
bution of T. infestans appears to have been reduced to
under 1 million Km2, with Chagas disease transmission
formally declared to have been halted in Uruguay, Chile,
most of Brasil, and substantial areas of Paraguay and
Argentina. Domestic transmission has also been substan-
tially reduced in Bolivia and southern Peru, although it
remains high in parts of the Chaco region of southern
Bolivia and northwestern Argentina [15,16].
The success of the Southern Cone Initiative helped to pro-
mote two similar multinational initiatives against Chagas
disease – in Central America and the Andean Pact region
– both launched in 1997, together with interstate initia-
tives in Mexico [17], and a large-scale Chagas disease sur-
veillance initiative for the countries of the Amazon basin
launched in 2002 [18]. The Central American Initiative
(Guatemala, Honduras, El Salvador, Belize, Nicaragua,
Costa Rica, Panama) is mainly targeted at the elimination
of Rhodnius prolixus (which is exclusively domestic in Cen-
tral America), elimination of domestic colonies of T.
dimidiata (which has widespread silvatic ecotopes and
cannot be targeted for complete area-wide elimination),
and also control of R. pallescens in Panama. At the time of
writing, R. prolixus appears to have been eliminated from
almost all of its previously-known distribution in Central
America, and house infestation rates with T. dimidiata
have been substantially reduced in all countries of the
region except Costa Rica [19]. The Andean Pact Initiative
(Colombia, Venezuela, Ecuador, Peru) has similar objec-
tives, but has been less successful, with only limited vector
control interventions being carried out.
Meanwhile, on the other side of the Atlantic, the initia-
tives against American trypanosomiasis were being care-
fully analysed by those involved with large-scale control
of the African trypanosomiases. In particular, the opera-
tional experience with Chagas disease control seemed to
show the importance of an area-wide approach (rather
than smaller projects of limited scope and duration), and
also the importance of a clear political mandate for mul-
tinational interventions.
Control of African trypanosomiasis (Sleeping Sickness and 
Nagana)
Attempts to control African trypanosomiasis have a long
history, dating from the colonial period when the Euro-
pean powers were concerned by epidemics of the human
disease and the chronic loss of livestock impeding both
transport and agriculture [20]. Their attempts – based
largely on active detection and treatment of sleeping sick-
ness cases, combined with major programmes to control
tsetse by bush-clearance (to eliminate tsetse resting sites),
wild game culling (to reduce the parasite reservoirs and
host availability for tsetse), and insecticidal spraying of
tsetse resting sites – were largely successful. Sleeping Sick-
ness case reports declined markedly from the 1920s to the
1960s, and considerable areas were cleared of tsetse –
especially in parts of northern Nigeria.
But following the wars of independence during the 1960s,
and the progressive withdrawal of colonial infrastructure,
case incidence of Sleeping Sickness began to rise (Fig. 2)
and routine tsetse control activities were interrupted in
many of the endemic countries. An important initiative by
Parasites & Vectors 2008, 1:24 http://www.parasitesandvectors.com/content/1/1/24
Page 4 of 7
(page number not for citation purposes)
the World Health Organization (WHO) led to steady
improvements in the supply of drugs to treat Sleeping
Sickness, such that by 1998 all such drugs could be offered
free-of-charge and WHO – in partnership with industry –
was able to offer increasing support for national medical
services involved in active detection and treatment. Since
1998, overall case reports of human Sleeping Sickness
have started to decline again (Fig. 2) although transmis-
sion rates remain high in parts of some countries – most
notably southern Sudan, Democratic Republic of Congo
(formerly Zaire), and northern Angola [4,21].
In parallel, a number of externally-financed projects to
control tsetse were set up in countries of interest to exter-
nal donor organisations – particularly in parts of franco-
phone Africa (eg. [22-24]], the Regional Tsetse and
Trypanosomiasis Control Programme of Zimbabwe, Zam-
bia, Mozambique and Malawi [25] and the various FITCA
projects (Farming in Tsetse Controlled Areas) supported
by the European Commission. Such projects were in
administratively-defined areas and were run for an
administratively-specified time. They were generally suc-
cessful whilst in operation, but generally proved unsus-
tainable once the formal project reached its endpoint, so
many were ultimately judged to be failures. Rather differ-
ent was the tsetse eradication project on the island of Zan-
zibar sponsored by the International Atomic Energy
Agency (IAEA). Although designed as a test-bed for tsetse
control by large-scale release of laboratory-reared radia-
tion-sterilised male tsetse (SIT) – and so proving rather
costly – the project succeeded in complete elimination of
tsetse (Glossina austeni) from the island [26] raising the
question of whether or not similar tsetse elimination
might be possible on mainland Africa.
Those involved were quick to realise the parallels with
American trypanosomiasis control. In both Africa and in
Latin America there had been a series of control projects
following administratively-defined boundaries (rather
than covering biologically-relevant areas) that had been
technically successful until being halted before a sustaina-
ble end-point had been reached. The Latin American
response came through multinational initiatives designed
to promote political continuity of action and to cover the
biologically relevant area represented by the entire distri-
bution of the target vector species. In Latin America, the
first step had been scientific debate [cf. [27]], followed by
the political mandate (Ministerial resolution number 04-
3-CS in 1991), designation of coordinating body
(PAHO), and work with each country within the man-
dated framework.
For Africa therefore, the idea of a Pan-African initiative
against tsetse and trypanosomiasis was discussed and rec-
ommended at the 25th ISCTRC (International Scientific
Council for Trypanosomiasis Research and Control) in
Mombasa, Kenya, in October, 1999. The recommenda-
tion was presented to the 36th summit of the OAU (Organ-
ization for African Unity, now African Union) in Lomé,
Togo, in July 2000. In response, the Heads of State and
Government of the 36 member states of the OAU passed
resolution AHG/Dec.156 XXXVI recognising the serious-
ness of the tsetse and trypanosomiasis problem, and call-
ing on member states "to act collectively...... to render Africa
tsetse-free within the shortest time possible". With this man-
date, the OAU set up the Pan African Tsetse and Trypano-
somiasis Eradication Campaign (PATTEC), which is now
an integral part of the AU Commission for Rural Develop-
ment.
PATTEC was formally launched at the 26th ISCTRC meet-
ing in Ouagadougou in October 2001, and its plan of
action endorsed by the OAU summits in Lusaka (OAU
Decision AHG/Dec.169/XXXVII) and Durban (OAU/AU
Decision CM/Dec.661/LXXVI.2002). The General Confer-
ences of the FAO and IAEA adopted resolutions in support
of the initiative (FAO 31st Gen.Conf. Res 4.2001; IAEA
45th Gen Conf. Res GC(45)/RES/12), as did the World
Health Assembly of WHO (Res WHA56.7).
The PATTEC mandate encompasses the whole of sub-
saharan Africa where tsetse are endemic, although it is
well recognised that it may not be feasible or necessary to
eradicate all tsetse species and populations, and that not
all regions are currently amenable to intervention. The
PATTEC vision is of long-term activities – extending per-
haps over 30–50 years – with the hope that during this
period each target area will present a suitable 'window of
opportunity' when political and economic stability will
permit large-scale interventions against tsetse and
The fall and rise (and fall) of African Sleeping SicknessFigure 2
The fall and rise (and fall) of African Sleeping Sick-
ness. Sleeping Sickness cases officially notified to WHO 
1940–2007 (figures courtesy of J. Jannin & P. Simarro, WHO 
Geneva). Note that WHO estimates the real prevalence may 
be up to 12 times the reported figure.
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trypanosomiasis [28]. No specific technical package is
defined, since elimination of each tsetse population will
have its own technical requirements, and each target
region has its own background, experience and practical
capabilities. Thus each target area will derive its own tech-
nical package, drawing from the wide range of available
control methods – including combinations of traps and
insecticide-impregnated targets, insecticide-treated cattle,
ultra-low dose aerial spraying (SAT) or ground-spraying
or fogging of tsetse resting sites, and SIT if feasible and
necessary for definitive elimination of the target popula-
tion. Much depends on the ability to define biologically
feasible targets – ie. tsetse populations that are sufficiently
geographically discrete that reinvasion would be unlikely,
or that occupy regions around which effective barriers
could be maintained until neighbouring areas can be
treated. To assist in this, PATTEC has set up a research net-
work supported by the Leverhulme Trust (LTTRN) [29]
that uses phenetic and genetic markers to assess geograph-
ical structuring of target tsetse populations [eg. [30,31]].
Although AU-PATTEC is still at an early stage, considera-
ble progress has been made, most notably in reviving
national programmes in a number of countries. Almost all
the tsetse-endemic countries now have designated PAT-
TEC focal points within the Ministry of Livestock and/or
Ministry of Health, and a series of multinational interven-
tions has begun with support from the national Govern-
ments. In addition, the African Development Bank has
provided a series of loans and grants totalling some $72
million to support tsetse elimination activities in Ethio-
pia, Kenya, Uganda, Mali, Burkina Faso, and Ghana, with
several other countries currently negotiating similar
arrangements. The new regional programmes include the
following:
- The 'Cotton Belt' of Mali, Burkina Faso, and northern
Ghana (main targets: G.p. gambiensis, G.m. submorsitans,
G. tachinoides) which is planned to extend progressively
also into Cote d'Ivoire, Guinea, and Senegal
- The Lake Victoria Basin, including parts of Kenya,
Uganda, Tanzania, and Ruanda (main targets: G.f. fuscipes,
G.m. submorsitans, G. pallidipes)
- Southern Rift Valley – southern Ethiopia and neighbour-
ing parts of Sudan (main target: G. pallidipes)
- The southeastern tsetse pocket (G. brevipalpis, G. austeni)
of southern Mozambique and northeastern South Africa
(KwaZulu Natal)
- The southern tsetse belt (G.m. centralis) of Botswana,
Namibia, western Zambia and southern Angola.
Of these, the southern programme is currently the most
advanced, and shows a clear example of what can be
achieved through multinational cooperation. The south-
ern G.m. centralis belt is extensive – over 40,000 km2 – but
relatively isolated from other tsetse populations. Control
operations had been in progress in northern Botswana
and western Zambia since the 1960s [20,32-34] but flies
were still abundant in many areas [35]. In 2000, the Gov-
ernment of Botswana initiated a new campaign designed
to eliminate G.m. centralis from the Okavango delta,
expecting then to deploy a series of trap barriers along the
frontiers to protect against reinvasion from neighbouring
countries. The control interventions, based on sequential
aerial spraying (SAT) and traps for monitoring tsetse den-
sities, appear to have been very successful, with no tsetse
encountered since completion of the interventions in June
2006 [36]. But the strategic approach has changed.
Instead of deploying barriers against reinvasion, the con-
trol programmes have now extended across the tsetse
infested Caprivi strip of Namibia, into southern Angola
and western Zambia, with the aim of eliminating the
entire G.m. centralis belt of the four countries [37,38]. The
programme is being almost entirely financed by the Gov-
ernments involved, with a high degree of cross-border
cooperation, including cross-border staff deployment.
Conclusion
The human trypanosomiases – Chagas disease in Latin
America, Sleeping Sickness in Africa – may be eliminated
as major public health problems within the next decade or
so. In Latin America, the campaigns have focused prima-
rily on vector control – elimination of domestic vector
populations by indoor insecticide spraying – although the
strategy is now changing to give additional emphasis to
detection and treatment of new cases that may occur as a
result of adventitious silvatic Triatominae entering houses
[16]. In Africa, Sleeping Sickness control relies primarily
on case detection and treatment, although it is increas-
ingly recognised that operational advances will more
likely be sustained where vector control is also carried out
effectively. But for the African animal trypanosomiases,
that contribute so much to poverty, underdevelopment,
and food insecurity, tsetse elimination is now seen as the
primary approach for the long-term. And in both conti-
nents – Latin America and Africa – accumulating experi-
ence is showing that large-scale elimination of vector
populations is feasible, and more likely to be sustainable
in the face of changing circumstances and priorities.
Comparing the two situations, both before and after the
current initiatives, may be premature in the light of on-
going interventions, but seems to reveal a series of key fea-
tures that may be conducive to success. Of paramount
importance is the political mandate, giving legitimacy to
large-scale interventions, and greatly assisting – although
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by no means guaranteeing – the continuity of action
required. This has been relatively weak for the Latin Amer-
ican initiatives, and requires constant reaffirmation as
national policies change. It is stronger for the PATTEC ini-
tiative, and the mandated requirement for annual report-
ing to the AU Heads of State and Government provides
regular opportunities for reaffirmation in the light of
progress achieved. The political mandate also influences
resource allocation, both in operational funds and the
executive personnel who implement the control interven-
tions. It is noteworthy that – so far – almost all funding for
the current trypanosomiasis control initiatives, both in
Latin America and in Africa, has come from national gov-
ernments – either from national budgets or repayable
loans.
Of parallel importance is the academic and research com-
munity. Where this is strong in some countries of Latin
America, it has greatly helped to promote continuity of
control interventions, as well as assisting in problem-solv-
ing and in programme monitoring and evaluation. Where
it is weak however, or disconnected from the control pro-
grammes, it can be a distraction and hindrance [39]. The
indication is that academia should be prepared to work
closely with the vector control services, such that their
activities will be mutually complementary, but with both
working to ensure continuity of intervention and effective
monitoring of progress. Of particular importance is that
the research responds to the practical needs of the control
programmes, rather than pursuing untried – and generally
unneeded – technical innovations.
The importance of the political mandate and of the aca-
demic community is perhaps equally relevant for the con-
trol of any vector-borne disease, but for the
trypanosomiases one further factor is of crucial impor-
tance. For both African and American trypanosomiasis,
the vectors are exquisitely vulnerable to currently availa-
ble control techniques. The low reproductive rates and
limited genetic variability of tsetse and of Triatominae
essentially restrict their ability to respond to the changing
circumstances imposed by available control interventions
[40]. This cannot be said of many other vectors, and
should be a key factor heralding the long hoped for suc-
cess.
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